Allos Therapeutics Inc

Premium Company Profile

Publication Date	April 2008
Publisher	Datamonitor
Product Type	Report
Pages	45
ISBN Number	not applicable
Product Code	DAT11465

Price

£265.00
approximately: $521 | €337

PDF

PRINT £315 ($619 | €400)

Order above formats by FAX

Summary

Introduction

Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of cancer. The company's lead product candidate, PDX, is currently in Phase II/I for various cancers. This product candidate offers huge opportunity for the company in achieving commercial success in the near future.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

The company's pipeline includes only two clinical stage product candidates: PDX and RH1. PDX (pralatrexate) is the company's lead product, currently in Phase II development as monotherapy for treating Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Mesothelioma, Non-Hodgkin Lymphoma, and Non-Small-Cell Lung Cancer. RH1 is being developed for solid tumors (Phase I). The company did not recognize any revenues for the historical period 2002-2006. The company's only contributor to the sales growth out to 2010 will be revenues from its lead product candidate, PDX. Revenues from PDX are expected to increase from 4.2 million in 2009 increasing to $78.1 million in 2010. The product is expected to be launched in the US during 2009.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .

Content

Overview
Catalyst
Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Company Financials
- Stock Market Performance
- P&l
- Balance Sheet
- Cash Flow
- Products & Services
- Pipeline Products
- Ac Forecast Product Sales
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Product Development
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
Appendix
- Ask The Analyst
- Datamonitor Consulting
- Disclaimer
Table of Figures
- Figure 1: Allos - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table of Tables
- Table 1: Allos - Key Facts
- Table 2: Allos - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 3: Allos - Key Events Impacting Share Price Performance
- Table 4: Allos - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 5: Allos - Balance Sheet, 2002-2006 ($ Mn)
- Table 6: Allos - Cash Flow, 2002-2006 ($ Mn)
- Table 7: Allos - in-House Pipeline Products
- Table 8: Allos - Forecast Sales, 2006-2010 ($ Mn)
- Table 9: Allos - Key Competitors
- Table 10: Allos - Key Suppliers
- Table 11: Allos - Key Shareholders
- Table 12: Allos - SWOT Analysis Summary
- Table 13: Allos - Value Chain Analysis
- Table 14: Allos - Key Employees
- Table 15: Allos - Financial and Operational Overview